GlassScriptPhysician profile
Angel Nunez
NPI 1366543456
$5,637.48
in general payments reported to CMS, 2019-2025
26 companies · $2,785 in 2025
The $2,785 reported for 2025 was more than what 82% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $283 · 2020: $297 · 2021: $254 · 2022: $587 · 2023: $657 · 2024: $774 · 2025: $2,785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $2,509 · Food and Beverage: $1,351 · Travel and Lodging: $358.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $2,508.88 |
| Food and Beverage | $1,350.66 |
| Travel and Lodging | $357.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,882.86 | 2024-2025 | |
| Glaxosmithkline, LLC. | $709.37 | 2019-2024 | Trelegy Ellipta, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $705.52 | 2019-2024 | Ofev, Jardiance |
| Astrazeneca Pharmaceuticals LP | $204.68 | 2019-2024 | Farxiga, Airsupra |
| Electromed, INC. | $178.31 | 2022-2024 | Smartvest |
| Novo Nordisk INC | $164.30 | 2022-2024 | Rybelsus, Ozempic |
| Philips North America LLC | $137.95 | 2020-2024 | (Ak6) Vest Therapy |
| Boston Scientific Corporation | $104.40 | 2019-2024 | Coredx |
| Amgen INC. | $100.99 | 2022-2024 | Repatha, Otezla, Tezspire |
| Genzyme Corporation | $63.35 | 2020-2024 | |
| Lilly USA, LLC | $54.57 | 2023-2024 | Mounjaro |
| Janssen Pharmaceuticals, INC | $44.13 | 2023-2024 | Xarelto |
| Grifols USA, LLC | $36.78 | 2020 | |
| Inspire Medical Systems, INC. | $34.15 | 2025 | Inspire |
| Regeneron Healthcare Solutions, INC. | $26.75 | 2024 | Dupixent |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $23.36 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $22.70 | 2022 | |
| Ethicon INC. | $19.87 | 2023 | Monarch Platform |
| Ethicon US, LLC | $17.88 | 2025 | Echelon; Endopath, Echelon Flex |
| United Therapeutics Corporation | $17.83 | 2022 | |
| Eisai INC. | $16.72 | 2020 | |
| Axsome Therapeutics, INC. | $16.70 | 2025 | Sunosi |
| Inogen, INC. | $15.80 | 2022 | |
| Resmed Corp | $13.75 | 2024 | |
| Fisher & Paykel Healthcare INC | $12.76 | 2020 | |
| Mylan Specialty L.P. | $12.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angel Nunez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.